Plain-English translation of NCT07165223 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called in people with type 2 diabetes who are currently using basal insulin (a long-acting insulin taken once or twice daily). The study will compare how well works compared to another insulin called Insulin Icodec, to see which one helps control blood sugar better and is safer for patients.
People with type 2 diabetes often need insulin to manage their blood sugar, but doctors are always looking for insulin options that work better, are easier to use, or have fewer side effects. This trial will help determine if the new treatment offers advantages over existing choices.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to receive either or Insulin Icodec, along with any other diabetes medications you may be taking. You would attend regular clinic visits for blood tests, blood pressure checks, and to discuss how you're feeling on the medication. The study will track how well your blood sugar is controlled and monitor you for any side effects throughout the treatment period.
AI-generated summary from trial data · Jun 1, 2026 · Not medical advice
China
Phase
Large-scale testing
Sponsor
Gan & Lee Pharmaceuticals.
Enrollment target
~300 participants
Started
October 2025
Primary completion
November 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
juan wu
Gan & Lee Pharmaceuticals.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.